Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
News|Articles|April 21, 2014
Roquette America and Quadra Ingredients Enter Partnership
Author(s)Pharmaceutical Technology Editors
Roquette America and Quadra Ingredients enter a partnership for the distribution of pharmaceutical products in Canada.
Advertisement
Roquette America
and Quadra Ingredients have entered apartnership for the distribution of pharmaceutical and personal care products in Canada.
The product range from Roquette provides solutions forformulators by addressing challenges such as enhancing stability, taste masking, organoleptic and disintegration enhancements, sugar-free delivery systems, clean label coatings, and cost reductions through improved performance. The product line includes excipients for use in various delivery systems used by the pharmaceutical, nutraceutical, and personal care markets, including tablets, capsules, soft gels, suspensions, liquids, powders, creams and ointments, orally dispersible tablets, and orally dispersible tablets, and parenteral.
Quadra Ingredients has a specialized sales and marketing team that will provide technical and regulatory support.
Source:
Roquette America
Advertisement
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Advertisement
Advertisement